View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Virbac : Declaration of the number of shares and voting rights 04/2025

Virbac : Declaration of the number of shares and voting rights 04/2025 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsApril, 30 20258 390 660Gross total of voting rights : 12 705 921Net total* of voting rights : 12 693 085...

 PRESS RELEASE

Virbac : Déclaration d'actions et de droits de vote 04/2025

Virbac : Déclaration d'actions et de droits de vote 04/2025 DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place cotation : Euronext ParisCompartiment ACode ISIN : FR0000031577 DATENombre total d’actions composant le capital socialNombre total de droits de vote30 Avril 20258 390 660Total brut de droits de vote : 12 705 921Total net* de droits de vote : 12 693 085 Total net* = nombre total de droits de vote attachés au no...

 PRESS RELEASE

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trial...

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week mainten...

 PRESS RELEASE

Virbac : Rapport Annuel Virbac au 31 décembre 2024 (ESEF)

Virbac : Rapport Annuel Virbac au 31 décembre 2024 (ESEF) Veuillez trouver le Rapport Annuel du Groupe au format ESEF au 31 décembre 2024. Pièce jointe

 PRESS RELEASE

Virbac : Public release of Virbac Annual Report at 31 December 2024

Virbac : Public release of Virbac Annual Report at 31 December 2024 The Group released and filed its 2024 Annual Report with the French “Autorité des marchés financiers”, at the ESEF Format. Additionally, the report is attached at the PDF format. The document is also available on the corporate website, at corporate.virbac.com, under “Investors”, “Financial Reports” at the ESEF format and PDF format. Attachments

 PRESS RELEASE

Virbac : Communiqué de mise à disposition du Rapport Annuel au 31 déce...

Virbac : Communiqué de mise à disposition du Rapport Annuel au 31 décembre 2024 Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format ESEF au 31 décembre 2024. Le rapport annuel est par ailleurs disponible dans sa version PDF en pièce jointe. Enfin, le rapport annuel peut être consulté sur le site internet du Groupe, à l’adresse corporate.virbac.com, dans la rubrique « Investisseurs», puis « Rapports financiers », au format XBRL et au format PDF. Pièces jointes ...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
 PRESS RELEASE

Abivax Announces Annual General Meeting Details as Company Advances To...

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage ...

 PRESS RELEASE

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directo...

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch